|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NAA10 |
Gene summary for NAA10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NAA10 | Gene ID | 8260 |
| Gene name | N-alpha-acetyltransferase 10, NatA catalytic subunit | |
| Gene Alias | ARD1 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | P41227 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8260 | NAA10 | Pt14.b | Human | Liver | HCC | 3.14e-04 | 2.70e-01 | 0.018 |
| 8260 | NAA10 | S014 | Human | Liver | HCC | 1.96e-19 | 7.97e-01 | 0.2254 |
| 8260 | NAA10 | S015 | Human | Liver | HCC | 3.80e-08 | 4.90e-01 | 0.2375 |
| 8260 | NAA10 | S016 | Human | Liver | HCC | 1.46e-03 | 3.32e-01 | 0.2243 |
| 8260 | NAA10 | S027 | Human | Liver | HCC | 1.22e-21 | 1.98e+00 | 0.2446 |
| 8260 | NAA10 | S028 | Human | Liver | HCC | 3.26e-33 | 1.64e+00 | 0.2503 |
| 8260 | NAA10 | S029 | Human | Liver | HCC | 1.11e-40 | 2.34e+00 | 0.2581 |
| 8260 | NAA10 | C04 | Human | Oral cavity | OSCC | 5.33e-45 | 2.90e+00 | 0.2633 |
| 8260 | NAA10 | C21 | Human | Oral cavity | OSCC | 2.13e-73 | 3.38e+00 | 0.2678 |
| 8260 | NAA10 | C30 | Human | Oral cavity | OSCC | 6.49e-57 | 3.60e+00 | 0.3055 |
| 8260 | NAA10 | C38 | Human | Oral cavity | OSCC | 1.11e-17 | 1.75e+00 | 0.172 |
| 8260 | NAA10 | C43 | Human | Oral cavity | OSCC | 7.16e-111 | 2.38e+00 | 0.1704 |
| 8260 | NAA10 | C46 | Human | Oral cavity | OSCC | 1.63e-43 | 1.17e+00 | 0.1673 |
| 8260 | NAA10 | C51 | Human | Oral cavity | OSCC | 2.22e-34 | 2.11e+00 | 0.2674 |
| 8260 | NAA10 | C57 | Human | Oral cavity | OSCC | 6.71e-22 | 9.88e-01 | 0.1679 |
| 8260 | NAA10 | C06 | Human | Oral cavity | OSCC | 2.77e-16 | 2.58e+00 | 0.2699 |
| 8260 | NAA10 | C07 | Human | Oral cavity | OSCC | 2.36e-08 | 2.28e+00 | 0.2491 |
| 8260 | NAA10 | C08 | Human | Oral cavity | OSCC | 5.09e-58 | 1.46e+00 | 0.1919 |
| 8260 | NAA10 | C09 | Human | Oral cavity | OSCC | 5.81e-12 | 6.39e-01 | 0.1431 |
| 8260 | NAA10 | LN22 | Human | Oral cavity | OSCC | 7.41e-14 | 1.75e+00 | 0.1733 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00330449 | Esophagus | HGIN | regulation of chromosome organization | 51/2587 | 187/18723 | 8.91e-07 | 3.61e-05 | 51 |
| GO:001063920 | Esophagus | HGIN | negative regulation of organelle organization | 79/2587 | 348/18723 | 4.12e-06 | 1.37e-04 | 79 |
| GO:005160417 | Esophagus | HGIN | protein maturation | 68/2587 | 294/18723 | 9.77e-06 | 2.86e-04 | 68 |
| GO:01400146 | Esophagus | HGIN | mitotic nuclear division | 61/2587 | 287/18723 | 3.38e-04 | 5.55e-03 | 61 |
| GO:00070593 | Esophagus | HGIN | chromosome segregation | 71/2587 | 346/18723 | 3.47e-04 | 5.62e-03 | 71 |
| GO:00064735 | Esophagus | HGIN | protein acetylation | 45/2587 | 201/18723 | 6.17e-04 | 8.58e-03 | 45 |
| GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
| GO:00064755 | Esophagus | HGIN | internal protein amino acid acetylation | 36/2587 | 160/18723 | 1.87e-03 | 2.01e-02 | 36 |
| GO:00000703 | Esophagus | HGIN | mitotic sister chromatid segregation | 36/2587 | 168/18723 | 4.42e-03 | 3.87e-02 | 36 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NAA10 | SNV | Missense_Mutation | c.281N>A | p.Ala94Asp | p.A94D | P41227 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NAA10 | SNV | Missense_Mutation | c.221C>T | p.Ser74Leu | p.S74L | P41227 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| NAA10 | SNV | Missense_Mutation | novel | c.385C>G | p.Gln129Glu | p.Q129E | P41227 | protein_coding | tolerated(0.51) | benign(0.001) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| NAA10 | SNV | Missense_Mutation | c.248N>A | p.Arg83His | p.R83H | P41227 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NAA10 | SNV | Missense_Mutation | novel | c.144N>T | p.Glu48Asp | p.E48D | P41227 | protein_coding | tolerated(0.21) | benign(0.021) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NAA10 | SNV | Missense_Mutation | rs369415038 | c.511N>A | p.Val171Met | p.V171M | P41227 | protein_coding | tolerated(0.1) | benign(0.022) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NAA10 | SNV | Missense_Mutation | c.92N>G | p.Tyr31Cys | p.Y31C | P41227 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-AX-A0IU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
| NAA10 | SNV | Missense_Mutation | novel | c.45G>T | p.Gln15His | p.Q15H | P41227 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NAA10 | SNV | Missense_Mutation | novel | c.137N>G | p.Glu46Gly | p.E46G | P41227 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| NAA10 | SNV | Missense_Mutation | novel | c.50N>A | p.Cys17Tyr | p.C17Y | P41227 | protein_coding | deleterious(0) | possibly_damaging(0.642) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |